Omaha, NENCT07581184Now EnrollingIRB Ready

Castration Resistant Metastatic Prostate Cancer Clinical Trial in Omaha, NE

Access cutting-edge castration resistant metastatic prostate cancer treatment through this clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.

Sponsored by Aktis Oncology, Inc.

Quick Self-Assessment

See if you qualify for this Omaha location

Preparing your pre-screening questions…

Expert Care in Omaha

Access castration resistant metastatic prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related castration resistant metastatic prostate cancer treatment provided free

Apply for This Omaha Location

Check if you qualify for this castration resistant metastatic prostate cancer clinical trial in Omaha, NE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Omaha

    Convenient for NE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Omaha site if eligible
  4. 4Begin participation

About This Castration Resistant Metastatic Prostate Cancer Study in Omaha

This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \[64Cu\]Cu-AKY-2519 and/or \[225Ac\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \[225Ac\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).

Sponsor: Aktis Oncology, Inc.

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
Histologic or cytologic confirmation of prostatic adenocarcinoma
ECOG Performance Status of 0 or 1
Adequate end-organ function
Ability to give informed consent and comply with study requirements
Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids
Castrate levels of serum testosterone (\< 50 ng/dL)
Documented disease progression on most recent prior line of therapy, either by PSA or imaging-based progression
Cohort B: Received 2 or more prior doses of 177Lu-PSMA-617 (PLUVICTO)

Exclusion Criteria

Prior treatment with more than 2 Androgen receptor pathway inhibitors (ARPIs) and/or more than 1 taxane-based therapy in the mCRPC setting
Prior treatment with a targeted radiotherapy o Exception: Cohort B is required to have had at least 2 prior doses of 177Lu-PSMA-617 (PLUVICTO)
Prior treatment with a B7-H3 targeted therapy
Received an investigational agent within the previous 28 days
Impaired cardiac function or clinically significant cardiac disease
Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT07581184) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Castration Resistant Metastatic Prostate Cancer Treatment Options in Omaha, NE

If you're searching for castration resistant metastatic prostate cancer treatment options in Omaha, NE, this clinical trial (NCT07581184) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced castration resistant metastatic prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all castration resistant metastatic prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Omaha, NE

See all prostate cancer clinical trials recruiting in Omaha — not just this study.

Browse Prostate Cancer Trials in Omaha →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Omaha?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Omaha, NE